---
title: "The GEO Compliance Foundation: Four-Fold Encirclement, Advertising Law Art.16, AI Labeling GB 45438-2025"
url: https://www.nine-health.cn/en/insights/geo-compliance-four-encirclement/
lang: en-US
type: Article
category: "White Paper Deep Read"
author: "Nine Health AI Digitalization Team"
authorRole: "GEO Methodology Research"
datePublished: 2026-10-11
dateModified: 2026-10-11
publisher: "和众利健科技（深圳）有限公司"
---

# The GEO Compliance Foundation: Four-Fold Encirclement, Advertising Law Art.16, AI Labeling GB 45438-2025

> **TL;DR** China has no GEO-specific regulation, yet four paths already fully constrain healthcare GEO (the four-fold encirclement). Advertising Law art.16 is the highest-risk clause (efficacy claims, cure rates, competitor comparison, endorsements all banned); the AI labeling rule + mandatory GB 45438-2025 is the top-priority compliance item, with dual-label duty falling on content publishers.

## Compliance is the legal chassis of healthcare GEO
{#overview}

The white paper calls Chapter 3 the "legal chassis" of the whole book. Every healthcare GEO action must sit within the regulatory framework. This article excerpts 3.1–3.4, on how the four-fold encirclement tightens and on the two highest-risk / top-priority red lines: Advertising Law art.16 and the AI labeling rule.

## Excerpt from the white paper
{#wp-excerpt}

China has no specific regulation for "generative engine optimization", yet four paths already fully constrain healthcare GEO: ①Advertising Law art.19 (disguised publishing); ②Internet Advertising Measures art.9 (identifiability); ③AI Labeling Measures (2025-09-01, explicit+implicit dual label, ban on deletion/tampering/fabrication); ④Clean-2026 (data-poisoning characterization).

Advertising Law art.16 core prohibitions: assertions or guarantees of efficacy/safety; stating cure or effective rates; comparing efficacy/safety with other drugs/devices; using endorsers for recommendation/proof; prescription drugs must state "for medical professionals only". A brand knowledge base fed to LLMs containing "92% effective" or "better than XX" becomes illegal once recited by AI.

Art.17: except for drugs/devices, no ad may touch disease-treatment function (the red line for supplements/cosmetics/food — "improves"/"anti-inflammatory" need a semantic-level sensitive-word library). Art.18: supplements must state "this product cannot replace drugs". Art.19 (the fatal clause): no disguised medical/drug/device/supplement advertising under the guise of health science.

Penalties (art.55/58): violating 16/17/18/19 with uncomputable ad cost → 100k–200k RMB; serious → 200k–1M RMB and license revocation; false advertising up to 1M–2M RMB. GEO "ad cost" is often hard to compute, so fixed penalties likely apply.

The AI-generated Content Labeling Measures (CAC 2025-2) took effect 2025-09-01, with mandatory GB 45438-2025. Dual-label duty: explicit (perceptible) + implicit (metadata: generator/service/ID); ban on malicious deletion/tampering/fabrication/hiding; duty binds not only AI providers but also content publishers — enterprises publishing AI-generated marketing material must self-check label integrity.

## Deep interpretation: build an "acceptable compliance paradigm" within the window
{#deep-dive}

First, the four-fold encirclement means "no specific law, but full constraint". The white paper's value proposition is clear: do not wait for legislation; find a compliant and effective path within the four existing paths. The most practical move is physical isolation of popular-science content from commerce — no purchase link or contact on the same page/segment (Internet Advertising Measures art.8).

Second, Advertising Law art.16 is the highest-risk clause because it directly constrains the LLM knowledge base. Many brands' AI knowledge bases carry "92% effective" / "better than competitor"; once recited and attributed to the brand, it is illegal and hard to disclaim. Correct approach: lock function-claim passages as "model-uneditable zones", using only guideline text, label text, expert-consensus authority.

Third, art.17/18/19 are the fatal clauses. Supplement "improves/anti-inflammatory/barrier-repair" and cosmetic "barrier-repair" need a semantic-level sensitive-word library — because LLM paraphrasing bypasses traditional word lists; the "cannot replace drugs" statement must be structurally embedded in cited sources, raising co-recall (both compliant and more visible).

Fourth, AI labeling GB 45438-2025 is top-priority and falls on content publishers. Many think "a watermark suffices", but the standard prescribes label position, size, wording format and implicit metadata fields. The white paper recommends an "labeling implementation checklist" — the current blind spot for most enterprises. Compliance must reach technical detail (watermark position/ratio, metadata field names).

Nine Health's framework: GEO content compliance SOP (self-check based on the Medical Advertising Recognition Guide) + AI labeling technical retrofit (GB 45438 dual label) + function-claim lock mechanism + corpus asset ledger (source/review/approval/reviewer/date). Documenting "provable compliance effort" is itself risk hedging.

## Get the full white paper
{#get-full}

This article excerpts chapters from the Nine Health white paper "Compliance as Growth: GEO Compliance & Growth in Healthcare" (2026 edition). The full edition covers the GEO tech stack, the compliance foundation, source engineering, the E-E-A-T trust system, and the eight capability-building modules, with a compliance self-check list, a three-color risk matrix, and a phased roadmap.

To request the full white paper or a one-on-one brand GEO diagnostic, contact Nine Health: phone 18126259547 / WeCom (see "Contact Us" on the site) / email jianyi@nine-health.com. Our team responds within 24 hours.

## Sources

- Nine Health white paper (2026), Chapter 3 (3.1–3.4): four-fold encirclement / Advertising Law art.16 / AI Labeling + GB 45438-2025
- PRC Advertising Law (2021 amend.) art.16/17/18/19/55/58
- AI-generated Content Labeling Measures (CAC 2025-2) and mandatory GB 45438-2025

## FAQ

### What are the "four-fold encirclement"?

①Advertising Law art.19 (disguised publishing); ②Internet Advertising Measures art.9 (identifiability); ③AI Labeling Measures (dual label, no tampering); ④Clean-2026 (GEO malicious marketing = data poisoning). Together they constrain healthcare GEO.

### Why is Advertising Law art.16 highest-risk?

It bans efficacy assertions, cure/effective rates, competitor comparison, endorser recommendation, and public-facing prescription ads. A knowledge base with "92% effective"/"better than rival" becomes illegal once AI recites it.

### What matters most for supplement GEO?

Art.17 red line: "improves/anti-inflammatory/barrier-repair" need a semantic-level sensitive-word library (LLM paraphrasing bypasses traditional lists); art.18 requires structurally embedding "this product cannot replace drugs".

### What does GB 45438-2025 require?

Explicit + implicit dual labeling of AI-generated content; ban on deletion/tampering/fabrication/hiding; duty binds content publishers. The standard prescribes label position, size, wording and metadata fields — not "just a watermark".

### How heavy are the penalties?

Uncomputable ad cost → 100k–200k RMB; serious → 200k–1M and possible license revocation; false advertising up to 1M–2M RMB. GEO ad cost is hard to quantify, so fixed penalties likely apply.

### What other compliance topics does the full white paper cover?

Chapter 3 also covers the Medical Advertising Recognition Guide, the 419 negative list, the Anti-Unfair-Competition Law, the MR Representative Measures, the three-color risk matrix, seven actions and Clean-2026 sentencing logic.

---

Source: [Nine Health](https://www.nine-health.cn/en/insights/geo-compliance-four-encirclement/) · Author: Nine Health AI Digitalization Team（GEO Methodology Research） · Publisher: 和众利健科技（深圳）有限公司